clinical trial · NCT06415344
Long-term Extension of GTX-102 in Angelman Syndrome
Angelman SyndromeGTX-102
brief summary
The primary objective of the study is to evaluate the long-term safety profile of GTX-102 in participants with Angelman Syndrome (AS)
started
Jul 31, 2024
primary completion
Feb 1, 2029
completion
Feb 1, 2029
last updated
May 6, 2026
detailed description
This study is a phase 3, long term extension (LTE) which is open to participants rolling over from a prior GTX-102 clinical study. The LTE study will evaluate the long-term safety and efficacy of GTX-102 in participants with AS.
official title
A Long-term Extension Trial Investigating the Safety and Efficacy of GTX-102 in Patients With Angelman Syndrome
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol